Grass Pollen Allergy is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Grass Pollen Allergy have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Grass Pollen Allergy compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Grass Pollen Allergy overview
Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions such as hives, redness, or swelling; itching or tingling in or around the mouth and throat; tightening of the throat; shortness of breath or wheezing; and runny nose. Predisposing factors include age, family history, and other allergies.
For a complete picture of PTSR and LoA scores for drugs in Grass Pollen Allergy, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.